

Universal Childhood schedule (All non-Indigenous children)	At risk Children ≤ 12 months All children with risk conditions Aboriginal and/Torres Strait Islander children in Qld	Children > 12 months, adolescents and adults of any age diagnosed with a risk condition (see page 2 for risk conditions)	Aboriginal and Torres Strait Islander adults without a risk condition	Non-Indigenous adults without a risk condition
13vPCV 2 months	13vPCV 2 months	13vPCV at diagnosis	13vPCV at age ≥ 50 years	13vPCV at age ≥ 70 years
13vPCV 4 months	13vPCV 4 months	23vPPV 2–12 months later, or at age ≥4 years, whichever is later	23vPPV 2 – 12 months later	
13vPCV 12 months	13vPCV 6 months	23vPPV at least 5 years later ¹	23vPPV at least 5 years later ¹	
	13vPCV 12 months			
	23vPPV at 4 years			
	23vPPV at least 5 years later			

1. Two doses of Pneumovax 23 maximum in a lifetime, if previous doses of Pneumovax 23 given to client they must be included in the maximum number received.

Time intervals between vaccine doses

- Prevenar 13 (13vPCV) given first then Pneumovax 23 (23vPPV) interval of 2 months
- Pneumovax 23 (23vPPV) given first then Prevenar 13 (13vPCV) interval of 12 months

Risk conditions for Pneumococcal	Eligibility for NIP funding	
	<5 years of age	≥5 years of age
Previous episode of invasive pneumococcal disease	Y	Y
Functional or anatomical asplenia, including		
– sickle cell disease or other haemoglobinopathies	Y	Y
– congenital or acquired asplenia (for example, splenectomy) or hyposplenia	Y	Y
Immunocompromising conditions, including		
– congenital or acquired immune deficiency, including symptomatic IgG subclass or isolated IgA deficiency	Y	Y
– haematological malignancies	Y	Y
– solid organ transplant	Y	Y
– haematopoietic stem cell transplant	Y	Y
– HIV infection	Y	Y
Proven or presumptive cerebrospinal fluid (CSF) leak, including		
– cochlear implants	Y	Y
– intracranial shunts	Y	Y
Chronic respiratory disease, including		
– suppurative lung disease, bronchiectasis and cystic fibrosis	Y	Y
– chronic lung disease in preterm infants	Y	Y
Chronic renal disease		
– relapsing or persistent nephrotic syndrome	Y	Y
– chronic renal impairment – eGFR <15 mL/min (stage 4 or 5 disease)	Y	Y
Cardiac disease, including		
– congenital heart disease	Y	
– coronary artery disease	Y	
– heart failure	Y	
Children born less than 28 weeks gestation	Y	
Trisomy 21	Y	

Note: Y = NIP funded vaccines